{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:13Z","timestamp":1793228113526,"version":"4.5.0"},"reference-count":96,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/17425247.2026.2659263","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:25:16Z","timestamp":1776101116000},"page":"1289-1303","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M.","family":"Ocio","sequence":"first","affiliation":[{"name":"Hospital Universitario Marqu\u00e9s de Valdecilla (IDIVAL), Universidad de Cantabria","place":["Santander, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep","family":"Parmar","sequence":"additional","affiliation":[{"name":"University of Wollongong","place":["Wollongong, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca\u2013Instituto Biosanitario de Salamanca","place":["Salamanca, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Poitiers University Hospital","place":["Poitiers, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tondre T.","family":"Buck","sequence":"additional","affiliation":[{"name":"Center for Hematology\/Oncology","place":["Spartanburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlyn Rose","family":"Tan","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Curry","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ling","sequence":"additional","affiliation":[{"name":"NSW Pathology","place":["Liverpool, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s Hospital Melbourne and University of Melbourne","place":["Fitzroy, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[{"name":"Poitiers University Hospital","place":["Poitiers, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Antoine, AP-HP, Sorbonne Universit\u00e9","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University Hospital H\u00f4tel-Dieu","place":["Nantes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65590-4"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2015.1122258"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1527198"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2022.100695"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-023-00616-z"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3150"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S302682"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.5731\/pdajpst.2024.012980"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2285277"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04033"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02810"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijn.12413"},{"issue":"4","key":"e_1_3_6_16_1","first-page":"SP352","article-title":"On-body delivery system enFuse saves time, improves QOL for patients","volume":"30","author":"Caffrey M","year":"2024","unstructured":"Caffrey M. On-body delivery system enFuse saves time, improves QOL for patients. Evidence-Based Oncol. 2024;30(4):SP352.","journal-title":"Evidence-Based Oncol"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284730"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2484278"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251326574"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1188\/21.CJON.663-671"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03365-w"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S453920"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00421"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6699"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_6_28_1","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) multiple myeloma version 5.2026 \u2014 January 9 2026. [cited 2026 Mar 31]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00744"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280660"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221107850"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0810-4"},{"key":"e_1_3_6_36_1","unstructured":"European Medicines Agency. Sarclisa. Updated 2025 Aug 28 [cited 2025 Nov 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sarclisa"},{"key":"e_1_3_6_37_1","unstructured":"European Medicines Agency. Sarclisa. Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma. 2022 [cited 2025 Mar 17]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-01-22-06-00-00-3013183?utm_campaign=sc_2024_copd&utm_source=linkedin_global&utm_medium=social&utm_content=300001552670789"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"e_1_3_6_41_1","unstructured":"PR Newswire. Sanofi: ANVISA aprova SARCLISA\u00ae em combina\u00e7\u00e3o ao VRd para o tratamento de pacientes com mieloma m\u00faltiplo rec\u00e9m-diagnosticados. 2024 [cited 2025 Mar 17]. Available from: https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/sanofi-anvisa-aprova-sarclisa-em-combinacao-ao-vrd-para-o-tratamento-de-pacientes-com-mieloma-multiplo-recem-diagnosticados\/"},{"key":"e_1_3_6_42_1","unstructured":"Sanofi. Sanofi Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma. 2025 [cited 2025 Nov 13]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-06-23-05-00-00-3103085"},{"key":"e_1_3_6_43_1","unstructured":"Sanofi. Sanofi Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant. 2024 [cited 2025 Nov 13]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-09-20-22-36-34-2949916"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0167"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.004"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000667"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70383-8"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1547108"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013503122"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41528-021-00107-x"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0097"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.01.007"},{"issue":"164","key":"e_1_3_6_54_1","first-page":"28","article-title":"Enhancing the patient and nurse experience in large-volume subcutaneous drug delivery","author":"Rahman O","year":"2024","unstructured":"Rahman O, Faiman B, Gorski L. Enhancing the patient and nurse experience in large-volume subcutaneous drug delivery. ONdrugDelivery. 2024(164):28\u201331.","journal-title":"ONdrugDelivery"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13109"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817735121"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.2147\/MDER.S479507"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059288"},{"key":"e_1_3_6_59_1","unstructured":"PR Newswire. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval 2023 [cited 2025 Mar 24]. Available from: https:\/\/www.prnewswire.com\/news-releases\/enable-injections-receives-first-us-food-and-drug-administration-fda-approval-301943533.html"},{"key":"e_1_3_6_60_1","unstructured":"Enable Injections. Enable Injections announces regulatory CE mark approval in Europe for enFuse technology. 2025 [cited 2025 Sep 22]. Available from: https:\/\/enableinjections.com\/enable-injections-announces-regulatory-ce-mark-approval-in-europe-for-enfuse-technology\/"},{"key":"e_1_3_6_61_1","unstructured":"Enable Injections. Enable Injections announces enFuse\u00ae system regulatory approval in Brazil and MRHA medical device registration in the UK. 2025 [cited 2025 Sep 22]. Available from: https:\/\/enableinjections.com\/enable-injections-announces-enfuse-system-regulatory-approval-in-brazil-and-mrha-medical-device-registration-in-the-uk\/"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-4044"},{"key":"e_1_3_6_63_1","unstructured":"Enable Injections. News release [cited 2025 May]. Available from: https:\/\/enableinjections.com\/a-new-frontier-self-administration-of-lyophilized-large-volume-subcutaneous-biologics"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01924-9"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7506"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03462-7"},{"key":"e_1_3_6_67_1","unstructured":"ClinicalTrials.gov. SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM (IRAKLIA). 2024 [cited 2025 Mar 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05405166?term=NCT05405166%20&rank=1"},{"key":"e_1_3_6_68_1","unstructured":"Taylor NP. VCs infuse $215M into Sanofi-backed wearable subcutaneous drug delivery player Enable Injections. Fierce Pharma. 2022 [cited 2025 Mar 25]. Available from: https:\/\/www.fiercepharma.com\/drug-delivery\/vcs-infuse-215m-into-sanofi-backed-wearable-subcutaneous-drug-delivery-player-enable"},{"key":"e_1_3_6_69_1","unstructured":"Apellis. EMPAVELI injector instructions for use 2025. [cited 2025 Sep 22]. Available from: https:\/\/pi.apellis.com\/files\/IFU_EMPAVELIinjector.pdf"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2402713"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1063144"},{"key":"e_1_3_6_75_1","volume-title":"Presented at the Annual Oncology Nursing Society (ONS) Congress","author":"Desai M","year":"2024","unstructured":"Desai M, Faiman B, Gorski L, et al. Evaluating nurse preferences: a novel on-body delivery system vs. High-resistance, manual syringes for large-volume subcutaneous drug administration. Presented at the Annual Oncology Nursing Society (ONS) Congress; Washington, (DC), USA. 2024 Apr 24\u201328. p. 23."},{"key":"e_1_3_6_76_1","unstructured":"Hamilton Company. \u00a92025. Needle Gauge Chart Knowledge Center. [cited 2025 Nov 19]. Available from: https:\/\/www.hamiltoncompany.com\/knowledge-base\/article\/needle-gauge-chart"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01436-0"},{"key":"e_1_3_6_78_1","first-page":"S31","volume-title":"Presentation at the International Myeloma Society (IMS) Annual Meeting. Clin Lymphoma Myeloma Leuk","volume":"25","author":"Bobin A","year":"2025","unstructured":"Bobin A, Durocher L, Ragot S, et al. Subcutaneous isatuximab flat dose by on-body injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: phase 2 ISASOCUT (IFM 2022\u201305) study. Presentation at the International Myeloma Society (IMS) Annual Meeting. Clin Lymphoma Myeloma Leuk; 2025. Vol. 25. p. S31\u2013S32."},{"key":"e_1_3_6_79_1","unstructured":"ClinicalTrials.gov. Multi-center open-label phase 1b study in patients with relapsed\/refractory multiple myeloma (RRMM). 2024 [cited 2025 Aug 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04045795"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02597-2"},{"key":"e_1_3_6_81_1","unstructured":"ClinicalTrials.gov. Lenalidomide bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in patients with newly diagnosed multiple myeloma. 2025 [cited 2025 Mar 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05804032"},{"key":"e_1_3_6_82_1","unstructured":"ClinicalTrials.gov. Iberdomide vs. iberdomide plus isatuximab maintenance therapy post ASCT in newly diagnosed multiple myeloma. 2025 [cited 2025 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06216158"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5812"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5826"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03970-9"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03952-7"},{"key":"e_1_3_6_87_1","unstructured":"ClinicalTrials.gov. Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib lenalidomide and dexamethasone in the treatment of newly diagnosed transplant ineligible multiple myeloma. 2024 [cited 2025 Aug 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05889221"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S317687"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0295-0"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276814"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.12.012"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.2147\/MDER.S198943"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2023.2184343"},{"key":"e_1_3_6_94_1","unstructured":"Enable Injections. Sustainability improvements in drug delivery: a waste comparison of IV vs. enFuse large-volume on-body delivery system. [cited 2025 Nov 20]. Available from: https:\/\/enableinjections.com\/sustainability-improvements-in-drug-delivery-a-waste-comparison-of-iv-vs-enfuse-large-volume-on-body-delivery-system\/"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2011-000089"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2024.100824"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgac006"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951520001315"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2659263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17425247.2026.2659263","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2659263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:56:55Z","timestamp":1782917815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2026.2659263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":96,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/17425247.2026.2659263"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2026.2659263","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}